BIOTE CORP -A (BTMD) Stock Fundamental Analysis
NASDAQ:BTMD - Nasdaq - US0906831039 - Common Stock - Currency: USD
Overall BTMD gets a fundamental rating of 6 out of 10. We evaluated BTMD against 193 industry peers in the Pharmaceuticals industry. BTMD has an average financial health and profitability rating. BTMD is growing strongly while it also seems undervalued. This is an interesting combination This makes BTMD very considerable for value and growth investing!
1. Profitability
1.1 Basic Checks
BTMD had positive earnings in the past year.
In the past year BTMD had a positive cash flow from operations.
Of the past 5 years BTMD 4 years were profitable.
BTMD had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of BTMD (13.68%) is better than 95.85% of its industry peers.
With an excellent Return On Invested Capital value of 43.56%, BTMD belongs to the best of the industry, outperforming 98.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.68% | ||
| ROE | N/A | ||
| ROIC | 43.56% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 6.85%, BTMD belongs to the best of the industry, outperforming 84.97% of the companies in the same industry.
In the last couple of years the Profit Margin of BTMD has declined.
BTMD has a better Operating Margin (16.78%) than 85.49% of its industry peers.
BTMD's Operating Margin has declined in the last couple of years.
BTMD has a better Gross Margin (71.27%) than 79.79% of its industry peers.
In the last couple of years the Gross Margin of BTMD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.78% | ||
| PM (TTM) | 6.85% | ||
| GM | 71.27% |
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
2. Health
2.1 Basic Checks
BTMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
BTMD has less shares outstanding than it did 1 year ago.
The debt/assets ratio for BTMD is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.92 indicates that BTMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
BTMD's Altman-Z score of 2.92 is fine compared to the rest of the industry. BTMD outperforms 72.02% of its industry peers.
BTMD has a debt to FCF ratio of 4.81. This is a neutral value as BTMD would need 4.81 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.81, BTMD belongs to the top of the industry, outperforming 83.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.81 | ||
| Altman-Z | 2.92 |
ROIC/WACC4.47
WACC9.74%
2.3 Liquidity
A Current Ratio of 1.42 indicates that BTMD should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.42, BTMD is doing worse than 69.95% of the companies in the same industry.
A Quick Ratio of 1.14 indicates that BTMD should not have too much problems paying its short term obligations.
BTMD's Quick ratio of 1.14 is on the low side compared to the rest of the industry. BTMD is outperformed by 72.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.14 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 490.91% over the past year.
Measured over the past years, BTMD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -48.53% on average per year.
BTMD shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.42%.
BTMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.38% yearly.
EPS 1Y (TTM)490.91%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%716.67%
Revenue 1Y (TTM)31.42%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%4.67%
3.2 Future
Based on estimates for the next years, BTMD will show a very strong growth in Earnings Per Share. The EPS will grow by 48.92% on average per year.
The Revenue is expected to grow by 9.89% on average over the next years. This is quite good.
EPS Next Y182.82%
EPS Next 2Y49.7%
EPS Next 3Y49.45%
EPS Next 5Y48.92%
Revenue Next Year3.12%
Revenue Next 2Y5.82%
Revenue Next 3Y8.84%
Revenue Next 5Y9.89%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 6.22 indicates a rather cheap valuation of BTMD.
Based on the Price/Earnings ratio, BTMD is valued cheaply inside the industry as 95.34% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.52, BTMD is valued rather cheaply.
With a Price/Forward Earnings ratio of 8.19, the valuation of BTMD can be described as very reasonable.
Based on the Price/Forward Earnings ratio, BTMD is valued cheaply inside the industry as 87.05% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of BTMD to the average of the S&P500 Index (35.58), we can say BTMD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.22 | ||
| Fwd PE | 8.19 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BTMD is valued cheaper than 90.16% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BTMD is valued cheaply inside the industry as 96.89% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.59 | ||
| EV/EBITDA | 7.58 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BTMD has a very decent profitability rating, which may justify a higher PE ratio.
BTMD's earnings are expected to grow with 49.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y49.7%
EPS Next 3Y49.45%
5. Dividend
5.1 Amount
No dividends for BTMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.04
-0.04 (-0.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners66.3%
Inst Owner Change0%
Ins Owners9.81%
Ins Owner Change8.21%
Market Cap204.46M
Analysts83.33
Price Target6.8 (68.32%)
Short Float %2.99%
Short Ratio5.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)228.05%
Min EPS beat(2)-1.96%
Max EPS beat(2)458.07%
EPS beat(4)2
Avg EPS beat(4)111.48%
Min EPS beat(4)-269.68%
Max EPS beat(4)458.07%
EPS beat(8)4
Avg EPS beat(8)19.41%
EPS beat(12)6
Avg EPS beat(12)-81.15%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.5%
Min Revenue beat(2)-4.66%
Max Revenue beat(2)1.66%
Revenue beat(4)1
Avg Revenue beat(4)-1.68%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)3
Avg Revenue beat(8)-1.48%
Revenue beat(12)5
Avg Revenue beat(12)-1.05%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-10.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.24%
EPS NY rev (1m)4.57%
EPS NY rev (3m)52.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.45%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.22 | ||
| Fwd PE | 8.19 | ||
| P/S | 0.83 | ||
| P/FCF | 5.59 | ||
| P/OCF | 4.61 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.58 |
EPS(TTM)0.65
EY16.09%
EPS(NY)0.49
Fwd EY12.2%
FCF(TTM)0.72
FCFY17.89%
OCF(TTM)0.88
OCFY21.68%
SpS4.86
BVpS-1.78
TBVpS-2.07
PEG (NY)0.03
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.68% | ||
| ROE | N/A | ||
| ROCE | 55.13% | ||
| ROIC | 43.56% | ||
| ROICexc | 98.25% | ||
| ROICexgc | 177.09% | ||
| OM | 16.78% | ||
| PM (TTM) | 6.85% | ||
| GM | 71.27% | ||
| FCFM | 14.86% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-32.05%
ROICexcg growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score6
Asset Turnover2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.81 | ||
| Debt/EBITDA | 3.22 | ||
| Cap/Depr | 210.54% | ||
| Cap/Sales | 3.15% | ||
| Interest Coverage | 4.43 | ||
| Cash Conversion | 98.57% | ||
| Profit Quality | 216.82% | ||
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | 2.92 |
F-Score6
WACC9.74%
ROIC/WACC4.47
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)490.91%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%716.67%
EPS Next Y182.82%
EPS Next 2Y49.7%
EPS Next 3Y49.45%
EPS Next 5Y48.92%
Revenue 1Y (TTM)31.42%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%4.67%
Revenue Next Year3.12%
Revenue Next 2Y5.82%
Revenue Next 3Y8.84%
Revenue Next 5Y9.89%
EBIT growth 1Y32.35%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year53.39%
EBIT Next 3Y25.44%
EBIT Next 5Y19.2%
FCF growth 1Y849.75%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y1512.04%
OCF growth 3Y10.29%
OCF growth 5Y12.28%